Researchers presented an intelligent AAV design framework that programs adeno‑associated viruses to respond to tumor microenvironment cues and activate selectively within malignancies. The approach addresses a central delivery challenge for gene therapies—off‑target expression—and leverages TME signals to gate vector activity. Preclinical data from the team show improved intratumoral targeting and reduced systemic exposure. The design framework could accelerate safer, more precise gene‑delivery strategies for oncology and expand AAV utility in solid tumors where tissue specificity has limited efficacy.